Compare ARBB & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBB | BIVI |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.7M |
| IPO Year | 2023 | N/A |
| Metric | ARBB | BIVI |
|---|---|---|
| Price | $6.09 | $1.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 37.6K | ★ 130.8K |
| Earning Date | 11-03-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,842,655.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 239.12 | N/A |
| 52 Week Low | $3.92 | $1.10 |
| 52 Week High | $18.60 | $22.90 |
| Indicator | ARBB | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 37.42 |
| Support Level | $5.80 | $1.14 |
| Resistance Level | $6.21 | $1.34 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 36.36 | 26.15 |
ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.